title: Target therapies in lung cancer.
abstract: Targeting intracellular signaling molecules is an attractive approach for treatment of malignancies. In particular lung cancer has reached a plateau regarding overall survival, and target therapies could offer the possibility to improve patients' outcome beyond cytotoxic activity. The goal for target therapies is to identify agents that target tumor-specific molecules, thus sparing normal tissues; those molecules are called biomarkers, and their identification is recommended because it has a predictive value, for example, provides information on outcome with regard to a specific treatment. The increased specificity should lead to decreased toxicity and better activity. Herein we provide an update of the main target therapies in development or already available for the treatment of nonsmall cell lung cancer.
authors.affiliation: Department of Medical Oncology, National Cancer Institute, CRO-IRCCS, Aviano, Italy. abearz@cro.it
authors.forename: A
authors.initials: A
authors.lastname: Bearz
authors.forename: M
authors.initials: M
authors.lastname: Berretta
authors.forename: A
authors.initials: A
authors.lastname: Lleshi
authors.forename: U
authors.initials: U
authors.lastname: Tirelli
mesh_terms: D000818:Animals; D006801:Humans; D008175:Lung Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000628:therapy*; D058990:Molecular Targeted Therapy; D009389:Neovascularization, Pathologic / Q000628:therapy; D015398:Signal Transduction